Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats

Clinical Nutrition

Volumn 22, Issue 5, 2003, Pages 463-471

  Rodriguez Cabezas M E ^a   Galvez J ^a   Camuesco, D ^a   Lorente, M D ^a   Concha, A ^b   Martinez Augustin, O ^a   Redondo, L ^c   Zarzuelo, A ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c Madaus Laboratories SA   (Spain)

Author keywords

Dietary fiber; HLA B27 transgenic rat; Inflammatory bowel disease; Short chain fatty acids; TNF

Indexed keywords

BUTYRIC ACID; HLA B27 ANTIGEN; ISPAGULA; LEUKOTRIENE B4; NITRIC OXIDE; PROPIONIC ACID; SHORT CHAIN FATTY ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOARCHITECTURE; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DIETARY FIBER; EXPERIMENTAL MODEL; FATTY ACID SYNTHESIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; NONHUMAN; PLANTAGO OVATA; RAT; REMISSION; TRANSGENIC ANIMAL; ULCERATIVE COLITIS;

EID: 0141960371     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0261-5614(03)00045-1     Document Type: Article

References (49)

1. Fiocchi C. Inflammatory bowel disease: aetiology and pathogenesis. Gastroenterology 1998; 115: 182-205
2. Elson C O, Sartor R B, Tennyson G S, Riddell R H. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344-1367
3. Sartor R B. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997; 92: 5S-11S
4. Bhan A K, Mizoguchi E, Smith R N, Mizoguchi A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 1999; 169: 195-207
5. 2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 63: 1099-1112
6. Aiko S, Grisham M B. Spontaneous intestinal inflammation and nitric oxide metabolism in HLA-B27 transgenic rats. Gastroenterology 1995; 109: 142-150
7. Aiko S, Fuseler J, Grisham M B. Effect of nitric oxide synthase inhibition of sulfasalazine on the spontaneous colitis observed in HLA-B27 transgenic rats. J Pharmacol Exp Ther 1998; 284: 722-727
8. Kerr S W, Wolyniec W W, Filipovic Z et al. Repeated measurement of intestinal permeability as an assessment of colitis severity in HLA-B27 transgenic rats. J Pharmacol Exp Ther 1999; 291: 903-910
9. Arseneau K O, Pazarro T T, Cominelli F. Discovering the cause of inflammatory bowel disease: lessons from animal model. Curr Opin Gastroen 2000; 16: 310-317
10. Taurog J D, Richardson J A, Croft J T et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-2364
11. MacDermott R P. Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol 1996; 31: 907-916
12. Mortensen P B, Clausen M R. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol 1996; 31: 132S-148S
13. Roediger W E W, Nance S. Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. Br J Exp Pathol 1986; 67: 773-782
14. Vernia P, Gnaedinger A, Hauck W, Breuer R I. Organic anions and the diarrhoea of inflammatory bowel disease. Dig Dis Sci 1988; 33: 1353-1358
15. Stonerook M J, Tefend K S, Sharma U M, Peck O C, Wood J D. Faecal short-chain fatty acids associated with inflammation in cotton-top tamarin model for idiopathic colitis. Dig Dis Sci 1996; 41: 618-624
16. Steinhart A H, Brzezinski A, Baker J P. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994; 89: 179-183
17. Patz J, Jacobsohn W Z, Gottschalk-Sabag S, Zeides S, Braverman D Z. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J Gastroenterol 1996; 91: 731-734
18. Fernandez-Bañares F, Hinojosa J L, Sanchez-Lombraña J L et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol 1999; 94: 427-433
19. Rath H C, Herfarth H H, Ikeda J S et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953
20. Krawisz J E, Sharon P, Stenson W F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87: 1344-1350
21. Chiesi M, Schwaller R. Inhibition of constitutive endothelial NO-synthase activity by tannin and quercetin. Biochem Pharmacol 1995; 49: 495-501
22. Bradford M M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-254
23. Mosman T. Rapid colorimetric assay for cellular-growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
24. Gessner P K. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 1995; 105: 161-179
25. Tallarida R J, Stone D J Jr, Raffa R B. Efficient designs for studying synergistic drug combinations. Life Sci 1997; 61: PL417-PL425
26. Hallert C, Kaldma M, Petersson B G. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991; 26: 747-750
27. Mitsuyama K, Saiki T, Kanauchi O et al. Treatment of ulcerative colitis with germinated barley foodstuff: a pilot study. Aliment Pharmacol Ther 1998; 12: 1225-1230
28. Kanauchi O, Andoh A, Iwanaga T et al. Germinated barley foodstuffs attenuate colonic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model. J Gastroenterol Hepatol 1999; 14: 1173-1179
29. Araki Y, Fujiyama Y, Andoh A, Koyama S, Kanauchi O, Bamba T. The dietary combination of germinated barley foodstuff plus Clostridium butyricum suppresses the dextran sodium-induced experimental colitis in rats. Scand J Gastroenterol 2000; 35: 1060-1067
30. Rodriguez-Cabezas M E, Galvez J, Lorente M D et al. Dietary fiber down-regulates tumor necrosis factor α and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J Nutr 2002; 132: 3263-3271
31. Ma Y. Intestinal epithelial barrier dysfunction in Crohn's disease. Proc Soc Exp Biol Med 1997; 214: 318-327
32. Gitter A H, Wullstein F, Fromm M, Schuylzke J D. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001; 121: 1320-1328
33. Hogaboam C M, Jacobson K, Collins S M, Blennerhassett M G. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol 1995; 268: G673-G684
34. Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995; 37: 247-255
35. Kimura H, Miura S, Shigematsu T et al. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease. Dig Dis Sci 1997; 42: 1047-1054
36. Pfeiffer C J, Qiu B S. Effects of chronic nitric oxide synthase inhibition on-induced colitis in rats. J Pharm Pharmacol 1995; 47: 827-832
37. Lobos E A, Sharon P, Stenson W F. Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4. Dig Dis Sci 1987; 32: 1380-1388
38. Van Deventer S J H. Tumor necrosis factor and Crohn's disease. Gut 1997; 40: 443-448
39. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-779
40. Chey W Y. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001; 7: 30S-33S
41. Rath H C, Ikeda J S, Linde H- J, Schölmerich J, Wilson K H, Sartor R B. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999; 116: 310-319
42. Hata K, Andoh A, Araki Y et al. Sequential changes in luminal microflora and mucosa cytokine expression during developing of colitis in HLA-B27/β2-microglobulin transgenic rats. Scand J Gastroenterol 2001; 36: 1185-1192
43. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002; 17: 818-824
44. Segain J P, Raingeard de la Bletiere D, Bourreille A et al. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut 2000; 47: 397-403
45. Inan M S, Rasoulpour R J, Yin L, Hubbard A K, Rosenberg D W, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology 2000; 118: 724-734
46. Huang N, Katz J P, Martin D R, Wu G D. Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine 1997; 9: 27-36
47. Hinnebusch B F, Meng S, Wu J K T, Archer S Y, Hodin R A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 2002; 132: 1012-1017
48. Rogler G, Brand K, Vogl D et al. Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 357-369
49. Choi C Y, You H J, Jeong H G. Nitric oxide and tumor necrosis factor-alpha production by oleanolic acid via nuclear factor-κB activation in macrophages. Biochem Biophys Res Commun 2001; 288: 49-55